Team

› navigate
Dr. Alexandra Goll

General Partner (based in Munich)

Dr. Alexandra Goll

General Partner (based in Munich)

Dr. Alexandra Goll, who joined TVM Capital in early 1998 has been responsible for more than 20 TVM Capital life science investments. She initiated TVM Capital’s lead investment in Actelion Ltd (Allschwil, Switzerland) and led the firm’s successful investments in Idenix Pharmaceuticals, Inc. sold to Novartis, and Pharmasset Inc. which was sold to Gilead Sciences – TVM Capital acted as a lead investor in both cases. She also initiated and managed the investment in EUSA Pharma Ltd., recently sold to Jazz Pharmaceuticals Inc.

Currently, Dr. Goll serves on the Board of Directors of Albireo (Gothenburg, Sweden), Biovertis AG (Vienna, Austria) and Cerenis Therapeutics (Toulouse, France and Ann Arbor, MI). She also represents the interests of TVM Capital with Addex Pharmaceuticals SA (Geneva, Switzerland) and Newron Pharmaceuticals SpA, (Bresso, Italy).

Prior to her affiliation with TVM Capital, Dr. Goll was the Global Business Leader for HIV and CMV, and was responsible for strategic marketing and business development for Virology at Roche Ltd. in Basel. She had been involved in clinical development and managing commercialization strategies of products such as Neupogen® (under an agreement with Amgen), Hivid®, Cymevene® and Valcyte®. Dr. Goll holds a degree in pharmacy from the Free University of Berlin, and wrote her doctoral dissertation in natural sciences at Philipps University of Marburg. She was also honored with a post-doctoral position supported by the Boehringer-Ingelheim Foundation for fundamental research in medicine.